WallSt.net Announces Upcoming Interview with President of Forticell Bioscience

NEW YORK, Jan. 22 /PRNewswire/ -- Dr. Costa Papastephanou, President and
Chief Executive Officer of Forticell Bioscience, Inc.
(OTC Bulletin Board: FORB) (http://www.forticellbioscience.com) will be
featured in an exclusive interview with www.wallst.net scheduled for January
23 at 2:00 p.m. EST. The interview will be posted on www.wallst.net by 8 p.m.
EST on January 23.
The interview will cover topics including Forticell's market potential,
growth initiatives, competitive edge, recent news, and milestones for which
investors should watch.
To hear the interview in its entirety, visit http://www.wallst.net and
click on "Interviews." The interview can be accessed by locating the company's
ticker symbol under the appropriate exchange at the top of the "Interviews"
section or by entering the company's ticker symbol in the Search Archive
window.
About Forticell Bioscience:
Forticell Bioscience, Inc. is focused on advancing regenerative medicine
and stem cell therapy through the development and commercialization of
innovative products by combining advanced cell technology and advanced
biomaterials. Forticell's lead product is OrCel(R) (Bilayered Cellular
Matrix). Forticell's current focus is the application of OrCel(R) to heal
chronic and acute wounds. OrCel(R) is composed of a collagen sponge seeded
with allogeneic epidermal and dermal cells. These cells secrete growth factors
and cytokines normally found in acute human wounds and are believed to have a
beneficial role in promoting tissue regeneration.
Through Forticell Bioscience's wholly owned Hapto subsidiary, the Company
is expanding its human tissue engineering capabilities with the development of
two fibrin derived advanced biomaterial technologies, Fibrin MicroBeads
(FMB(TM)) and Haptides(TM). These peptides have demonstrated the ability to
significantly enhance cell attraction and attachment providing the potential
to use Haptides(TM) in the development of product opportunities applicable to
the cosmetic tissue augmentation and reconstruction, wound healing,
orthopedics, and drug delivery markets.
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly
owned subsidiary of Financial Media Group, Inc. The Website is a leading
provider of timely business news, executive interviews, multimedia content,
and research tools. Financial Media Group, Inc. also owns
http://www.mywallst.net, a financial social network for investors, Financial
Filings Corp., a provider of compliance solutions to publicly traded
companies, and WallStRadio, a business and finance podcast Website. Financial
Filings Corp. is expecting to receive two hundred eighty dollars from
Forticell Bioscience, Inc. for the dissemination of this press release. For a
complete list of our advertisers and advertising relationships, visit
http://www.wallst.net/disclaimer/disclaimer.asp.
Contact: WallSt.net
800-4-WALL-ST

SOURCE WallStreet Direct, Inc.

WallSt.net, 1-800-4-WALL-ST